SOMERSET, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that Bill Korn, Chief Strategy Officer and Larry Steenvoorden, Chief Financial Officer will be participating in the Sidoti Virtual Investor Conference, taking place on Wednesday, August 16, 2023 and Thursday, August 17, 2023, including a presentation on Thursday, August 17, 2023 at 10:45 a.m. EDT. They will also be available for one-on-one meetings to discuss CareCloud’s strategy and business performance both days.
To arrange a meeting with Bill and Larry, investors can contact Bridget Forde at This email address is being protected from spambots. You need JavaScript enabled to view it.. To view the replay of this presentation, please visit CareCloud’s investor relations site at ir.carecloud.com/events, and click on Sidoti Virtual Investor Conference.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
For additional information, please visit our website at www.carecloud.com. To view CareCloud’s latest investor presentations, read recent press releases, and listen to interviews with management, please visit ir.carecloud.com.
Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.11 |
| Daily Volume: | 0 |
| Market Cap: | US$131.860M |
November 06, 2025 October 20, 2025 October 15, 2025 September 29, 2025 September 25, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
